Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 2/20 | 0.67 |
| ▸ | RET | P07949 | 4/20 | 0.57 |
| ▸ | EPHA2 | P29317 | 12/20 | 0.54 |
| ▸ | KDR | P35968 | 6/20 | 0.54 |
| ▸ | EPHB4 | P54760 | 4/20 | 0.54 |
| ▸ | EGFR | P00533 | 1/20 | 0.52 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6881994 | 1.00 | SRC (0.67) | SRCRETEPHA2KDREPHB4 | |
| SCHEMBL3673200 | 0.85 | EGFR (0.69) | SRCRETEPHA2KDREPHB4 | |
| SCHEMBL6876069 | 0.84 | KDR (0.69) | SRCEPHA2KDREPHB4EGFR | |
| SCHEMBL6876064 | 0.84 | KDR (0.69) | SRCEPHA2KDREPHB4EGFR | |
| SCHEMBL5221992 | 0.82 | KDR (0.66) | SRCRETEPHA2KDREPHB4 | |
| SCHEMBL3674907 | 0.80 | SRC (0.86) | SRCKDREPHB4EGFR | |
| SCHEMBL6878556 | 0.80 | SRC (0.61) | SRCRETKDREGFR | |
| SCHEMBL3677246 | 0.80 | SRC (1.00) | SRCKDREGFR | |
| SCHEMBL3730315 | 0.80 | SRC (0.85) | SRCKDREGFRERBB2 | |
| SCHEMBL3680459 | 0.80 | SRC (0.85) | SRCRETKDREPHB4EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063733-A1 | Such as 4-(7-indolylamino)-6-methoxy-7-(3-morpholinopropoxy)-quinazoline; for treating solid tumors | ASTRAZENECA AB (SE) | 2004-04-01 | — | — | US | disclosed |
| EP-1332141-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2003-08-06 | — | — | EP | disclosed |
| WO-2002034744-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063733-A1 | Such as 4-(7-indolylamino)-6-methoxy-7-(3-morpholinopropoxy)-quinazoline; for treating solid tumors | MIF, CCNI, MMP7 | SRC 1355/4885RET 2507/4885EPHA2 1744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.